Technical Analysis for BPTH - Bio-Path Holdings Inc
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.98 | 8.23% | 0.07 |
BPTH closed up 8.23 percent on Friday, November 1, 2024, on 11 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 13
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New Uptrend | Bullish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Gapped Up | Strength | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
MACD Bearish Centerline Cross | Bearish | 8.23% | |
New Downtrend | Bearish | 8.23% | |
Stochastic Reached Oversold | Weakness | 8.23% | |
Wide Bands | Range Expansion | 8.23% | |
Down 3 Days in a Row | Weakness | 8.23% | |
Down 4 Days in a Row | Weakness | 8.23% |
Alert | Time |
---|---|
Gap Up Partially Closed | about 22 hours ago |
Gapped Up (Partial) | 1 day ago |
Rose Above Previous Day's High | 1 day ago |
Up 5% | 1 day ago |
Up 3% | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/13/2024
Bio-Path Holdings, Inc., a biotechnology company, focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Its lead product candidate, Liposomal Grb-2, is in a Phase I study for blood cancers and in preclinical studies for triple negative and inflammatory breast cancers. The company's other drug candidate, Liposomal Bcl-2, is ready for the clinic where it would be evaluated in lymphoma and solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Houston, Texas.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Solid Tumors Acid Breast Cancer Lymphoma Cell Biology Treatment Of Breast Cancer Therapeutic Products Oncogenes Blood Cancers Apoptosis
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Solid Tumors Acid Breast Cancer Lymphoma Cell Biology Treatment Of Breast Cancer Therapeutic Products Oncogenes Blood Cancers Apoptosis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 13.692 |
52 Week Low | 0.846 |
Average Volume | 1,497,629 |
200-Day Moving Average | 3.13 |
50-Day Moving Average | 1.01 |
20-Day Moving Average | 1.07 |
10-Day Moving Average | 1.04 |
Average True Range | 0.09 |
RSI (14) | 44.75 |
ADX | 26.81 |
+DI | 21.70 |
-DI | 20.46 |
Chandelier Exit (Long, 3 ATRs) | 1.17 |
Chandelier Exit (Short, 3 ATRs) | 1.11 |
Upper Bollinger Bands | 1.24 |
Lower Bollinger Band | 0.91 |
Percent B (%b) | 0.22 |
BandWidth | 30.85 |
MACD Line | -0.01 |
MACD Signal Line | 0.00 |
MACD Histogram | -0.0148 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.09 | ||||
Resistance 3 (R3) | 1.08 | 1.03 | 1.07 | ||
Resistance 2 (R2) | 1.03 | 1.01 | 1.04 | 1.06 | |
Resistance 1 (R1) | 1.01 | 0.99 | 1.02 | 1.02 | 1.06 |
Pivot Point | 0.96 | 0.96 | 0.97 | 0.97 | 0.96 |
Support 1 (S1) | 0.94 | 0.94 | 0.95 | 0.95 | 0.90 |
Support 2 (S2) | 0.89 | 0.92 | 0.90 | 0.90 | |
Support 3 (S3) | 0.87 | 0.89 | 0.89 | ||
Support 4 (S4) | 0.88 |